QGEN Stock Slumps After-Hours On Guidance Cut Tied To Weak TB Test Demand
QIAGEN N.V. (QGEN) shares fell about 6% after hours after it cut fiscal 2026 guidance. The company now expects adjusted diluted EPS of at least $2.43 at constant exchange rates, down from $2.50, and net sales growth of 1-2% versus at least 5%. It cited weaker QuantiFERON TB test demand, including lower U.S. immigration testing. Q1 net sales were $492M and adjusted EPS $0.54 CER.
How this was made
The 30-second read
Why it matters
The guidance cut is explicitly tied to lower-than-expected QuantiFERON demand, including weaker immigration testing in the US and Middle East, plus broader customer caution and geopolitical/tariff and supply-cost headwinds.
Market read
A company-specific FY and Q2 guidance reduction tied to a named product demand shortfall is a direct catalyst for estimate revisions and near-term positioning.
What to watch
The article cites multiple offsetting items (new launches, supply reliability, acquisition contribution), so the market may be over-weighting the near-term demand miss versus the stated 2H recovery plan.
Background
Qiagen is a diagnostics and life-sciences tools company, with QuantiFERON TB testing as a key revenue driver.
Ticker impact
Qiagen cut FY2026 guidance to adjusted EPS at least $2.43 and net sales growth to 1-2% after weaker QuantiFERON TB test demand.
Further downside or elevated volatility is plausible until investors gain clarity on US immigration testing demand and the timing of 2H normalization.
The article provides specific, company-issued FY and Q2 guidance reductions directly linked to QuantiFERON sales declines, which typically drives estimate revisions and multiple compression.
Market effects
Diagnostics and life-sciences tools peers may face read-across risk if investors generalize weaker TB testing demand or US life-sciences caution.
US and Middle East immigration testing demand weakness is cited as a key driver, focusing attention on those geographies.
Geopolitical uncertainty and tariffs are cited, which can broaden risk-off positioning in global diagnostics demand.
Counterpoint
Management points to sequential QuantiFERON improvement and 2H growth support from discontinued product headwinds ending and Parse Biosciences contributions, which could limit the duration of the selloff.
Key entities
- companyQIAGEN N.V.
Cut fiscal 2026 guidance due to weaker QuantiFERON tuberculosis test demand and reduced sales growth expectations.
- productQuantiFERON tuberculosis test
TB test whose sales fell 5% CER to $113 million, cited as the main driver of the guidance reduction.
- corporate eventParse Biosciences acquisition
Management cites contributions from the acquisition as support for stronger 2H 2026 growth trends.
